logo
Famed analysts and investors have been putting their names on ETFs. Here's what it takes for a fund to succeed.

Famed analysts and investors have been putting their names on ETFs. Here's what it takes for a fund to succeed.

Business Insider20 hours ago

A string of widely followed strategists, economists, and investors have launched exchange-traded funds in recent years.
There's famed NYU professor Nouriel Roubini — known colloquially as " Dr. Doom" — and his Atlas America Fund (USAF).
Then there's Dan Ives — the tech and AI permabull who can often be found on CNBC wearing fluorescent blazers — who has parlayed his bold analyst calls into the Wedbush AI Revolution ETF (IVES).
And let's not forget Fundstrat's Tom Lee — former chief equity strategist at JPMorgan — and his Granny Shots US Large Cap ETF (GRNY).
They've stepped into a crowded market with thousands of funds competing for investors' money. A record 723 ETFs came to market in 2024 alone. And they're using their own high-profile personal brands to stand out in a crowded marketplace.
But starting a fund is an entirely different beast than keeping one afloat for any sustained amount of time. Yes, strong performance is crucial. But running a fund is expensive, and it takes much more than good returns to ensure success.
To start, the cost to launch a fund is hefty. Firms are looking at a $50,000-to-$100,000 filing fee with the SEC, according to Zachary Evans, analyst for passive strategies at Morningstar. ETF.com puts that number between $100,000 and $500,000. Depending on the type of fund, there also may be an initial listing fee with NYSE or Nasdaq.
But the bills don't stop there. Listing fees with the exchange come due every year. With Nasdaq, for example, it's a $4,000 annual fee.
Then there's a long list of costs associated with running the fund itself, Evans said. Paying the staff who execute the trades. Paying compliance and a risk-management team. Paying sales and advertising teams to market the fund. Paying rent for your office space. And so on.
It all adds up, and it means funds need to amass significant assets under management. ETF providers make money through the annual fees, or expense ratios, they charge investors. So the more money they manage, the more money they're bringing in. Performance also plays a role here — if a fund's value rises by 20% in a year, the fees it extracts will be 20% higher.
"This can vary quite a bit, but a baseline number we've heard is that it should cost around $200,000 a year to run an ETF," Evans told BI. "More complicated strategies will cost more, simpler strategies will cost less, or if it's from a large firm that has economies of scale, it might cost less as well."
He added: "Say an ETF charges 50 basis points with annual expenses of $200,000 a year. You need $40 million AUM in order to break even on that product."
For some funds, there's also pressure associated with seed money. When an ETF launches, Evans said it might have some investors who promise to keep their capital locked up in the fund for a set period of time — say two or three years. Once that period ends, if the investors pull their money, it can be an existential threat to a fund if they haven't pulled in enough money from elsewhere.
"Once that seed money dries up, in order for them to endure, they need to make sure they have enough investor interest, enough assets to sustain them," Evans said.
Fund closures are increasingly common. Evans said a little more than 200 closed in 2023 — a record — and just under 200 closed in 2024.
"As more companies are launching their products, more companies are closing down their products — the vast majority of which have really failed to catch on with investors," Evans said. "They've failed to generate either the performance or, in effect, the asset level to support these products."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Prime Success Responds to Sinovac Biotech's False and Misleading Claims
Prime Success Responds to Sinovac Biotech's False and Misleading Claims

Business Wire

time2 hours ago

  • Business Wire

Prime Success Responds to Sinovac Biotech's False and Misleading Claims

HONG KONG--(BUSINESS WIRE)--Prime Success L.P., (together with its affiliates, 'Prime Success' or 'we'), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) ('Sinovac' or the 'Company') with ownership of approximately 8% of the Company's outstanding shares, today issued the following letter in response to the Company's recent false and misleading claims relating to the upcoming Special Meeting of Shareholders (the 'Special Meeting') scheduled for July 8, 2025. The full text of the letter is below and available at Dear fellow Sinovac shareholders, Prime Success, L.P. (together with its affiliates, 'Prime Success' or 'we'), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) ('Sinovac' or the 'Company'), continues to be disappointed by the current Board's ('1Globe Activist Board') distortion of the facts about what is at stake at the upcoming Special Meeting of Shareholders (the 'Special Meeting') scheduled for July 8, 2025. In our June 10 letter we addressed several of the 1Globe Activist Board's misstatements and are taking the opportunity to remind all shareholders why the 1Globe Activist Board cannot be trusted: 1. Prime Success is insisting that a dividend be distributed – for all shareholders The 1Globe Activist Board's false comments are just not credible – why would any investor be against receiving a dividend? The 1Globe Activist Board wants you to believe that Prime Success is the reason that dividends have not been distributed, but we are not the Company and are not on the Board, and dividend distribution decisions are not ours to make. We can only continue to advocate on behalf of all shareholders that they should be made. Under the leadership of a SAIF Partners IV L.P. ('SAIF') nominated Board — composed of seasoned professionals with proven governance experience, deep operational insight, and a track record of building real, lasting value — we are confident that the pattern of internal conflict and ongoing litigation fueled by the 1Globe Activist Board can be broken, and shareholders can look forward to more future dividends. But that will not be possible with the 1Globe Activist Board in power as they have made clear they prioritize endless litigation over the Company's long-term success. 2. The 1Globe Activist Board is deliberately baiting shareholders by setting the dividend distribution date for one day after the Special Meeting. We call upon the Company to make dividend distribution before the Special Meeting The 1Globe Activist Board deliberately set the dividend date for one day after the Special Meeting which creates the false impression that shareholders must vote for the incumbents to receive the dividends. But the upcoming Special Meeting will determine the Company's future direction and the long-term interests of all shareholders. We call on the 1Globe Activist Board to allow for a fair, pro rata distribution of dividends and to move the date of the dividend distribution to before the Special Meeting so the meeting can refocus on its proper purpose: electing a competent Board. 3. The 1Globe Activist Board distorts historic facts to aggrandize 1Globe and smear legitimate investors Let's compare facts against rhetoric of the 1Globe Activist Board. Over the past seven years, what have we contributed to the Company? The critical lifeline investments from Prime Success and Vivo Capital, LLC, combined with management's determined efforts, enabled Sinovac to seize a pivotal opportunity: the development of CoronaVac. This initiative ultimately resulted in the delivery of billions of doses to over 60 countries, generating substantial revenues while saving countless lives. Without the success of CoronaVac, there would not be any sizable dividend to distribute now. In contrast, what has 1Globe done for the Company? It has initiated multi-jurisdictional litigation against Sinovac, leading to a waste of company resources. The 1Globe Activist Board's mischaracterization of 1Globe and Prime Success' relative contribution to Sinovac and its shareholders reveals its deeply partisan nature. 4. Shareholders: looking forward, it's time to focus on what truly matters – the future of your investment in Sinovac Sinovac needs a Board that will roll up its sleeves and run the business, guiding the Company forward on a stable, productive path. The slate put forward by SAIF, consisting of representatives from all shareholders owning more than 5% of the Company's equity stake, many of whom possess deep industry experience, achieves exactly that. We urge all shareholders to focus on the future and choose the leadership that will best secure our Company's success in the years to come. We look forward to continuing to make our case for change to our fellow shareholders and encourage them to wait for and read SAIF's proxy materials before voting for the Special Meeting on July 8, 2025. Sincerely, Prime Success, L.P. About Prime Success, L.P. Prime Success is an investment vehicle established by Advantech Capital specifically to invest in Sinovac and Sinovac Life Sciences; Advantech Capital is a private equity fund established in 2016 with a focus on innovation-driven growth opportunities in China.

Think Lucid Group Stock Is Expensive? This 1 Chart Might Change Your Mind.
Think Lucid Group Stock Is Expensive? This 1 Chart Might Change Your Mind.

Yahoo

time3 hours ago

  • Yahoo

Think Lucid Group Stock Is Expensive? This 1 Chart Might Change Your Mind.

Lucid Group stock looks expensive. Tesla's history shows Lucid's true potential. 10 stocks we like better than Lucid Group › Everyone wants to invest in the next Tesla (NASDAQ: TSLA), and an examination of analyst predictions suggests Lucid Group (NASDAQ: LCID) has the potential to be it. Sales are expected to grow by 73% this year, with another 96% growth expected in 2026. There's just one problem with buying the stock at the moment: Lucid shares trade at 6.7 times sales, a pricey valuation for a business that might be unprofitable for at least the next several years. If you dig deeper, however, Lucid shares might be wildly undervalued despite the high price-to-sales ratio (P/S). Despite generating less than 1% of Tesla's revenue, Lucid Group still trades at roughly half the valuation of Tesla on a price-to-sales basis. That could all change when the company releases its "mass market" vehicles. Management has previously teased three new vehicle models that will all sell for less than $50,000 a piece. While these vehicles are still a year or two away from production, they should eventually put Lucid's growth in overdrive. Tesla released its Model 3 in 2017, with the Model Y following in 2020. These two affordable vehicles now account for more than 90% of Tesla's sales -- the primary reason that Tesla's sales have gone from a few billion dollars to more than $95 billion today. Lucid has a very long way to go before matching Tesla's revenue numbers. But releasing more affordable models is the key to closing the gap. If management is to be believed, the first of several mass market models will arrive sometime in 2026, with more on the way in 2027 and beyond. It should be stressed that Lucid's financial position isn't incredibly strong right now. It has less than $1.9 billion in cash on the balance sheet, yet it lost nearly $2.4 billion over the last 12 months. More cash will need to be raised to get these new models to market. However, Tesla's success shows Lucid's true potential. Before you buy stock in Lucid Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lucid Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. Think Lucid Group Stock Is Expensive? This 1 Chart Might Change Your Mind. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Caesars Entertainment (CZR) Shares Jump on 'Buy' Reco
Caesars Entertainment (CZR) Shares Jump on 'Buy' Reco

Yahoo

time3 hours ago

  • Yahoo

Caesars Entertainment (CZR) Shares Jump on 'Buy' Reco

We recently published a list of . In this article, we are going to take a look at where Caesars Entertainment, Inc. (NASDAQ:CZR) stands against other top-performing companies on Tuesday. Caesars Entertainment rallied by 5.7 percent on Tuesday to close at $28.26 apiece as investors cheered bullish outlooks from two investment companies. In a market note, TD Cowen reaffirmed its 'buy' recommendation and $40 price target on Caesars Entertainment, Inc.'s (NASDAQ:CZR) stock, underscoring the company's robust cash flow and digital potential. The figure represented a 41.5 percent upside from its latest closing price. Meanwhile, JMP Securities also maintained its 'market outperform' rating on Caesars Entertainment, Inc. (NASDAQ:CZR) at a price target of $45, representing a 59-percent premium of its closing price on Tuesday. Given the continued softening in summer bookings, JMP Securities was confident about Caesars Entertainment, Inc.'s (NASDAQ:CZR) pricing strategy for non-gaming business segments, which has already been successful in the past. A general view of a luxury resort casino, surrounded by a beautiful landscape and illuminated at night. Additionally, the convention and group outlook, which has seen a year-to-date increase of 2 percent, is expected to serve as a medium-term catalyst for the company, potentially reaching record levels by 2026. Caesars Entertainment, Inc. (NASDAQ:CZR) is a hotel and gambling operator that operates more than 50 properties. Overall, CZR ranks 7th on our list of top-performing companies on Tuesday. While we acknowledge the potential of CZR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store